UNSPSC 51393411: Bamifylline hydrochloride

This classification denotes a bronchodilator with the molecular formula C20H27N5O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66466QLM3S, chemically known as 1h-purine-2,6-dione, 7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)-3,7-dihydro-1,3-dimethyl-8-(phenylmethyl)-, monohydrochloride but more generally known as bamifylline hydrochloride, which bears US NIH Compound Identifier 68549. The base compound, Bamifylline, most often comes in base and hydrochloride forms.

UNSPSC 51393411 Bamifylline hydrochloride is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though recent opportunities tagged under this code show a significant mismatch between the code's nominal scope and the work actually being solicited. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of naloxone and safe drug deactivation systems—a public health supply chain acquisition unrelated to bamifylline hydrochloride. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to solicit vendor input on establishing direct-to-manufacturer pharmacy prescription programs, a strategic sourcing initiative focused on pharmacy benefit management rather than a specific pharmaceutical commodity. The code appears to reflect misclassification rather than active procurement demand in the pharmaceutical wholesale or retail space. State and local issuing bodies using this code include county health departments and state health agencies; the recent record shows minimal repeat buyer activity under the code itself.

Geographic activity is concentrated in the Southwest and Southeast regions, with documented solicitations from Florida and Texas in the first half of 2026. Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, though posted June 30, 2026) represents an operational procurement with a two-year initial term and one-year renewal option, delivered quarterly to a health building in Sanford, Florida. The Texas HHS RFI is exploratory rather than a binding procurement and does not carry a response deadline with binding force. The mismatch between the code name and the actual solicitations—naloxone and deactivation systems in one case, and strategic pharmacy benefit management in the other—suggests this code shows limited relevant recent activity for vendors in the pharmaceutical manufacturing or wholesale space. Business development professionals should verify code classification in specific opportunities before investing pursuit effort, as tagging accuracy appears inconsistent in this category.